Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2018 | Nonmetastatic CRPC: meeting an unmet need

Eric Small • 8 Feb 2018
GU Cancers 2018
Genitourinary Cancer Prostate Cancer Apalutamide Enzalutamide
PROSPER SPARTAN

Nonmetastatic castration-resistant prostate cancer (nmCRPC) is a disease which had no FDA-approved treatment. Following the completion of the Phase III SPARTAN trial (NCT01946204), a new nonsteroidal antiandrogen (NSAA) treatment, apalutamide, is showing promise in this area. In this exciting interview, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses how the encouraging results of this study will impact the treatment and outcomes of patients with nmCRPC. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Eric Small

Straightforward study design: SPARTAN trial of apalutamide for nmCRPC
2:11
Straightforward study design: SPARTAN trial of apalutamide for nmCRPC
Eric Small • 8 Feb 2018
This is SPARTAN! Apalutamide treatment for nmCRPC
3:40
This is SPARTAN! Apalutamide treatment for nmCRPC
Eric Small • 8 Feb 2018
How will the results of the SPARTAN study impact US clinical practice in prostate cancer?
1:22
How will the results of the SPARTAN study impact US clinical practice in prostate cancer?
Eric Small • 8 Feb 2018
SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC?
1:31
SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC?
Eric Small • 8 Feb 2018

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals